Obesity and Prevalence of Latent Tuberculosis: A Population-Based Survey

Alaa Badawi,1,2 and Christina J Liu3

1Public Health Risk Sciences Division, Public Health Agency of Canada, Toronto, ON, Canada.
2Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, ON, Canada.
3Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, ON, Canada

ABSTRACT:

OBJECTIVE: Diminution in body weight is a known risk factor that increases the burden of active tuberculosis (TB). However, conflicting evidence exists for the effect of body weight on the risk of latent tuberculosis infection (LTBI). The objective of the present study is to examine the prevalence of LTBI at different body weights, evaluate the extent of association between body mass index (BMI) and LTBI and identify factors mediating this relationship in an adult population.

METHODS: We conducted a cross-sectional study to estimate the relationship between BMI and LTBI in participants from the US-National Health and Nutrition Examination Survey (NHANES; 2012, n = 5156; 514 with LTBI and 4642 controls).

RESULTS: The association between BMI and levels of cardiometabolic risk markers in both LTBI and control groups had a similar profile. When adjusted for age and sex, BMI was significantly inversely correlated with the prevalence of LTBI (r = −0.147, P < .001). Effect of BMI on the risk of LTBI was evaluated using multivariate logistic regression models adjusted for age, sex, diabetes, and level of education. In this model, increasing BMI was significantly associated with lower risk of LTBI (OR = 0.85; 95% CI: 0.77-0.96, P < .01).

CONCLUSION: This study further establishes an inverse relationship between BMI and prevalence of LTBI. Decreased BMI can be considered as a risk factor in LTBI, the reservoir for active TB cases.

KEYWORDS: Tuberculosis, obesity, body mass index, adults

Introduction

Presently, tuberculosis (TB) is among the leading causes of death from a single infectious pathogen globally.1 Although TB control has significantly improved over the past 2 decades, rendering the disease more preventable, TB is still responsible for more than a million deaths each year especially in low-income countries.1,2 According to World Health Organization estimates, the number of TB incident cases in 2018 worldwide was 10.0 million, with more than 1.2 million deaths.2 This burden, however, varies from country to country by a number of individual- and population-related factors including age, sex, location, HIV infection, extent of drug-resistance, and country’s sociodemographic and economic status.1 Approximately 30% of persons exposed to Mycobacterium tuberculosis infection develop a state of persistent immune response to stimulation by the pathogen’s antigen without evidence of clinically manifested TB and remain clinically asymptomatic (ie, with latent tuberculosis infection, LTBI).3 However, 10% of the persons with LTBI will progress to active TB disease, presenting with clinical signs and symptoms.4 Individuals with LTBI represent a reservoir for TB cases. The detection and management of LTBI is a component in the World Health Organization’s “End TB Strategy” aiming to reduce worldwide TB incidence by 90% and TB mortality by 95% between 2016 and 2035.5 Detection of active cases has been the primary public health response to TB. However, reducing the LTBI reservoir is fundamental in order to reach the ambitious goal of the “End TB Strategy.”6

Several sociodemographic and metabolic risk factors have been proposed to influence the development of LTBI. Those included race, marital status, age, history of TB contact, urban residency, job category, and high (>7%) glycosylated hemoglobin (HbA1c).7-11 Malnutrition12 and the subsequent acute or chronic diminution in body weight13-15 have also been proposed as factors that influence the development of TB. For example, an overall inverse relationship between TB and body mass index (BMI) has been depicted from studies carried out in diverse populations with a large variation in the average LTBI prevalence from Hong Kong, USA, Finland, and Norway.15,16 Although the interplay between the 2 conditions is unclear, including whether low weight is a risk factor and/or an effect in LTBI, there is a general consensus that—at a population level—higher BMI is linked to lower prevalence of LTBI.17

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CORRESPONDING AUTHOR: Alaa Badawi, Public Health Risk Sciences Division, Public Health Agency of Canada, 180 Queen Street West, Toronto, ON M5V 3L7, Canada and Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. Emails: alaa.badawi@canada.ca; alaa.badawi@utoronto.ca

Key Points

- Obesity is inversely correlated with the prevalence of LTBI.
- Decreased BMI can be considered as a risk factor in LTBI.

Acknowledgments

This study was supported by the Public Health Agency of Canada (AB).

Conflict of interest

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Public Health Agency of Canada (AB).
Several lines of evidence support an association between BMI and the development of LTBI.12-20 Cardiometabolic risk markers associated with obesity—such as fasting insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and fasting triglycerides—are all linked to increased prevalence of diabetes mellitus.26 Diabetes increases the risk of both LTBI and TB and has been associated with adverse treatment outcomes, including death.21-23 Obesity upregulates cardiometabolic markers that both reduce T-helper-1 cytokine production in response to infection and impair the respiratory burst to expel the pathogens.24 These observations suggest a utility for BMI and the related cardiometabolic risk markers in identifying subjects at risk of LTBI upon exposure to \textit{M. tuberculosis}. The objective of the present study is to examine the prevalence of LTBI at different body weights, evaluate the extent of association between BMI and LTBI and identify factors mediating this relationship in an adult population.

**Methods**

**Study population**

Data were collected from the US National Health and Nutrition Examination Survey (NHANES), a cross-sectional survey of the noninstitutionalized civilian US resident population. The survey is designed to collect information on the health and wellness as well as nutrition status of the populations. The NHANES survey is conducted by the National Center for Health Statistics (NCHS), CDC. The survey examines a nationally representative sample of approximately 5000 individuals of all age groups each year from counties across the USA (15 of which are visited each year). All of the study methods have been approved by the NCHS research ethics review board. All participants provided informed consent and were selected by using a complex multistage sampling design.25 This survey includes an in-home health interview and a physical examination in a mobile examination center (MEC) in addition to a follow-up telephone interview. The present study included data from the 2011/2012 cycles of NHANES. This cycle includes QuantiFERON®-TB Gold-In-Tube (QFT-GIT) to measure LTBI.26 Detailed methods of the NHANES survey construction and sampling strategy have been previously described.27,28 This survey cycle was a stratified, multistage, probability random sample designed to represent the noninstitutionalized house-dwelling US civilian population. In this analysis, we included all eligible participants from the 2011/2012 cycle of NHANES who were adults (>18 years), completed the interview and health examination, had valid QFTGIT (positive/negative) and weight and height data. The total number of participants included in the present study was 5156 subjects (male:female ratio of 1:1.06). The study participants were further divided to controls (n = 4642) and LTBI (n = 514) subgroups.

**Study measures, metabolic markers, sociodemographic factors, and other covariates**

Body mass index (kg/m²) was assessed as previously described.28 We used the international classification of adult underweight, normal weight, overweight, and obesity according to BMI ranges as defined by the World Health Organization (WHO) where the cut-off points were ≤18.50, 18.50 to 24.99, 25.00 to 29.99, and ≥30.00 kg/m², respectively. Assessment for the status of LTBI was carried out by QFT-GIT, analyzed according to manufacturer instructions (QuantiFERON®-TB Gold [QFT®] ELISA; QIAGEN, Germantown, MD, USA—www.quantiferon.com). Results were interpreted according to guidelines from the Centers for Disease Control and Prevention (CDC) for using interferon-gamma release assays (IGRAs).29 Individuals with indeterminate QFTGIT results and those who self-reported they had ever been told by a health care professional to had TB were excluded. Samples for QFT-GIT testing were processed at a Clinical Laboratory Improvement Act-certified laboratory as previously described.30

A number of metabolic markers were measured including cardiometabolic risk factors (apolipoprotein [Apo] B1 [g/L], LDL-C [mmol/L], HDL-C [mmol/L], T-Chol [mmol/L], T-Chol:HDLC ratio, triglycerides [mmol/L], and HbA1c [%]); and systolic and diastolic blood pressure (mmHg). Diabetes status was defined as a self-reported (information on use of insulin and oral diabetes agents) or HbA1c ≥6.5%.31 Individuals who have already been diagnosed as hypertensive, diabetic, or those who were using antihypertensive drugs were included.32-34 Insulin resistance (IR) was approximated using the homeostatic model assessment (HOMA-IR) formula (glucose [mmol/L] \times insulin [\mu IU/mL] \div 22.5).35,36 Liver functions were evaluated in both survey studies using serum enzyme markers of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase, and \( \gamma \)-glutamyl transferase. Furthermore, a number of serum micronutrients and minerals were measured and captured in the present study including vitamin B12 (pmol/L), red blood cells (RBC), folate (nmol/L), folic acid (nmol/L), folate (nmol/L), sodium (mmol/L), potassium (mmol/L), and calcium (mmol/L). Sociodemographic information was captured through responses to questionnaires given during the structured interview portion of the survey and included: age, gender, race, education, history of injection drug use, and ratio of family income to poverty. Race was categorized into 4 main subgroups: White, African Americans, Asian (ie, Korean, Filipino, Japanese, Chinese, South Asian, Southeast Asian, Arab, and West Asian), and Hispanic and Other (ie, Latin American or mixed race). Ratio of family income to poverty was assessed as determined by the Department of Health and Human Services to be used as a measure of poverty.37 Self-reported smoking status was categorized into smokers (daily/occasional) and non-smokers.38
Statistical analysis

All analyses were stratified by LTBI status and survey weights were excluded from the analysis. Frequency distributions and means (± standard deviation, SD) were used to describe baseline characteristics. Differences between groups (controls and LTBI for the entire study population and at different BMI ranges) for examined sociodemographic characteristics and levels of biomarkers and cardiometabolic risk factors were determined using *t*-test and *χ*² tests for continuous and categorical variables, respectively. Fisher’s exact test was used for categorical data analysis where there were small sample sizes. Bivariate Pearson correlation adjusted for age, sex, and ethnicity was used to explore the association between BMI and cardiometabolic risk markers in the control and LTBI groups. Correlational analysis between BMI and LTBI or BMI and the cardiometabolic risk markers was carried out to estimate Pearson correlation coefficient (r). Partial correlation was used to adjust the analysis for age, sex, and ethnicity. Multivariable logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) between BMI and LTBI adjusted for potential confounders. Covariates included in multivariable models as confounders were chosen from observed bivariate associations between BMI and LTBI. The degree of missing data was assessed for each variable and was considered for multivariable regression model inclusion. If a variable had >80% missing data, it was not included in the regression model. There was no statistically significant difference between the proportion of missing data and LTBI status, thus data were considered missing at random. All analyses were conducted using SPSS (IBM SPSS Statistics, Version 21.0. Armonk, NY, USA).

Results

Characteristics of the control and LTBI groups

A total of 5156 respondents were examined in the present study. The prevalence of LTBI was approximately 10% (n = 514). In the underweight, normal weight, overweight, and obese subgroups, the prevalence of LTBI was 10.6%, 10.2%, 10.6%, and 9.1%, respectively. There was no difference in LTBI prevalence within each weight subgroup. Baseline sociodemographic characteristics and levels of biomarkers and cardiometabolic risk factors of the study population, stratified by LTBI status, are shown in Table 1. Individuals with LTBI were, on average, older than control counterparts (*P* < .001) and subjects with older age were significantly more prevalent in the LTBI group compared to controls (*P* < .001). The control group was predominantly Whites (39.1%) whereas in subjects with LTBI, Black, and Asians were more prevalent, constituting >50% of the group. There was a higher percentage of subjects with less than grade 12 education in the LTBI compared to controls and lower percentage of those with post-secondary education. The ratio of family income to poverty was significantly lower in the LTBI group than controls (*P* = .036). Approximately 1.7-fold significantly higher (*P* < .001) prevalence of diabetes was noted in the LTBI group than controls. In the present study diabetes was defined as self-reported or participants with Hb1Ac ≥ 6.5%. No significant differences were shown between LTBI and control group in the examined cardiometabolic risk markers except for the levels of fasting triglycerides that was significantly higher in the LTBI than controls (1.44 ± 0.85 vs 1.42 ± 1.06, *P* < .001). Insulin resistance (HOMA-IR) was significantly higher in the LTBI group than controls (31.1 ± 83.9 vs 22.1 ± 26.9; *P* = .0423). Levels of micronutrients such as vitamin B12 and folate and activities of liver enzymes such as alanine aminotransferase and γ-glutamyl transferase were all significantly higher in the LTBI group compared to controls. Levels of RBC folate and serum folic acid were significantly lower in the LTBI group than in controls.

Characteristics of the study population stratified by BMI

Sociodemographic characteristics and levels of cardiometabolic risk markers in LTBI and controls, stratified by the different BMI ranges, are shown in Table 2. Overall, there was a higher percentage of males and persons of older age in the LTBI group than controls in all BMI subgroups. In both normal weight and overweight subgroups, there was a significantly higher percentage of Whites in the control group (LTBI OR for Whites = 0.56; 95%CI: 0.47-0.67; *P* < .001) but more Asians in the LTBI group (LTBI OR for Asians = 4.59; 95%CI: 3.59-5.88; *P* < .001). In contrast, in the obese subgroup, there was a higher percentage of Blacks in the LTBI group (LTBI OR for Blacks = 1.21; 95%CI: 0.89-1.72; *P* = .141) but more Whites in the control obese subgroup (LTBI OR for Whites = 0.35; 95%CI: 0.23-0.54; *P* < .001). LTBI groups had lower education levels (using highest education as a reference category; LTBI OR for lower education = 1.67; 95%CI: 1.39-2.01; *P* < .001). Although all BMI subgroups showed a lower ratio of family income to poverty compared to controls, this difference was only significant in the obese subgroup (*P* = .0167). Prevalence of diabetes ranged from 1.6- to 8.3-fold higher in the LTBI group than in controls, across all the BMI subgroups. The highest prevalence of diabetes was noted in the obese subgroups compared to other BMI ranges. Differences in the cardiometabolic risk markers between LTBI and controls were principally noted in the normal weight and overweight subgroups. This was particularly apparent in the increased levels of triglycerides, cholesterol (T-Chol:HDL-C), fasting glucose, and HbA1C levels in the LTBI group and the HDL in the control group of normal weight and overweight subgroups.
**Table 1.** Sociodemographic characteristics and levels of potential cardiometabolic risk factors stratified by presence or absence of latent tuberculosis infection, U.S. National Health and Nutrition Examination Survey (NHANES), 2011/2012.

| CHARACTERISTIC                        | CONTROLS (N=4642) | LTBI (N=514) | Pr  |
|---------------------------------------|-------------------|--------------|-----|
|                                       | N     | %* OR MEAN ± SD | N     | %* OR MEAN ± SD |       |
| Males (%)                             | 2259  | 48.7           | 236   | 45.7           | <.001 |
| Age (years)                           | 4642  | 46.1 ± 18.5    | 514   | 55.8 ± 15.7    |       |
| Age group (years)                     |       |                |       |                |       |
| 18-30                                 | 1196  | 25.8           | 38    | 7.4            | <.001 |
| 31-50                                 | 1552  | 33.4           | 137   | 26.7           |       |
| 51-70                                 | 1328  | 28.6           | 249   | 48.4           |       |
| >70                                   | 566   | 12.2           | 90    | 17.5           |       |
| Ethnicity (%)                         |       |                |       |                |       |
| White                                 | 1816  | 39.1           | 73    | 14.2           | <.001 |
| Black                                 | 1218  | 26.2           | 122   | 23.8           |       |
| Asian                                 | 564   | 12.2           | 143   | 27.8           |       |
| Hispanic and other                    | 262   | 5.9            | 105   | 2.2            |       |
| Highest level of education (%)        |       |                |       |                |       |
| Less than grade 12                    | 927   | 19.9           | 190   | 36.5           | <.001 |
| High-school graduate                  | 923   | 19.8           | 104   | 20.0           |       |
| Post-secondary graduate               | 2530  | 54.4           | 215   | 41.3           |       |
| Ratio of family income to poverty     | 4282  | 2.42 ± 1.6     | 454   | 2.19 ± 1.5     | .036  |
| History of intravenous drug use (%)   | 61    | 1.3            | 9     | 1.7            |       |
| Smoking status (%)                    |       |                |       |                |       |
| Daily/occasional                      | 872   | 18.8           | 102   | 19.6           | .003  |
| Non-smoker                            | 972   | 20.9           | 138   | 26.5           |       |
| Diabetes (%)—self-reported or HbA1c ≥ 6.5% c | 653   | 14.1           | 127   | 24.4           | <.001 |
| Cardiometabolic risk markers          |       |                |       |                |       |
| Systolic blood pressure (mmHg)        | 4276  | 123 ± 18       | 477   | 126 ± 19       |       |
| Diastolic blood pressure (mmHg)       | 4276  | 71 ± 13        | 477   | 71 ± 13        |       |
| Triglycerides, fasting (mmol/L)       | 2258  | 1.42 ± 1.06    | 239   | 1.44 ± 0.85    | <.001 |
| Total cholesterol (mmol/L)            | 4553  | 4.95 ± 1.08    | 503   | 5.04 ± 1.04    |       |
| LDL-C (mmol/L)                        | 2216  | 2.92 ± 0.91    | 237   | 2.93 ± 0.89    |       |
| HDL-C (mmol/L)                        | 4553  | 1.36 ± 0.38    | 503   | 1.32 ± 0.37    |       |
| Total cholesterol:HDL-C ratio         | 4553  | 3.87 ± 1.29    | 504   | 4.05 ± 1.30    |       |
| Insulin, fasting (pmol/L)             | 2174  | 81.6 ± 72.0    | 232   | 84.1 ± 69.9    |       |
| Glucose, fasting (mmol/L)             | 2284  | 5.93 ± 1.87    | 244   | 6.32 ± 2.05    |       |

(Continued)
### Table 1. (Continued)

| CHARACTERISTIC                      | CONTROLS (N=4642) | LTBI (N=514) | \( p \) |
|-------------------------------------|-------------------|--------------|--------|
|                                     | N                 | % OR MEAN ± SD | N     | % OR MEAN ± SD |
| HOMA-IR                             | 2172              | 22.1 ± 26.9  | 234   | 31.1 ± 83.9    | .0423 |
| HbA1c (%)                           | 4630              | 5.73 ± 1.10  | 514   | 6.03 ± 1.23    |       |
| Apolipoprotein B, fasting (g/L)     | 2259              | 0.89 ± 0.25  | 239   | 0.90 ± 0.23    |       |
| Obesity                             |                   |              |       |                |
| Body mass index (kg/m²)             | 4642              | 28.7 ± 7.0   | 514   | 28.5 ± 6.7     |       |
| Underweight: BMI: <18.5 kg/m² (%)   | 101               | 2.18         | 12    | 2.33           |       |
| Normal weight: BMI: 18.5-24.9 kg/m² (%) | 1422          | 30.63        | 162   | 31.46          |       |
| Overweight: BMI: 25-29.9 kg/m² (%)  | 1488              | 32.06        | 177   | 34.37          |       |
| Obese: BMI: >30 kg/m² (%)           | 1631              | 35.13        | 163   | 31.66          |       |
| Vitamins and minerals               |                   |              |       |                |
| Vitamin B12 (pmol/L)                | 4266              | 464 ± 363    | 493   | 470 ± 313      | <.001 |
| RBC folate (nmol/L)                 | 4603              | 1099 ± 509   | 511   | 1072 ± 450     | <.001 |
| Folic acid, serum (nmol/L)          | 4499              | 2.51 ± 10.4  | 499   | 2.04 ± 5.61    | <.001 |
| Serum folate (nmol/L)               | 4495              | 45.7 ± 28.2  | 498   | 46.4 ± 23.5    | .023  |
| Sodium (mmol/L)                     | 4523              | 139 ± 2      | 501   | 139 ± 3        |       |
| Potassium (mmol/L)                  | 4522              | 3.93 ± 0.35  | 501   | 3.95 ± 0.35    |       |
| Calcium (mmol/L)                    | 4523              | 2.35 ± 0.09  | 501   | 2.33 ± 0.10    |       |
| Liver enzyme markers                |                   |              |       |                |
| Alanine aminotransferase (U/L)      | 4522              | 24.6 ± 26.6  | 500   | 25.2 ± 20.9    | <.001 |
| Alkaline phosphatase (U/L)          | 4523              | 67.5 ± 24.3  | 501   | 69.8 ± 23.2    |       |
| Aspartate aminotransferase (U/L)    | 4520              | 25.5 ± 16.7  | 500   | 26.5 ± 17.3    |       |
| \( \gamma \)-Glutamyl transferase (U/L) | 4522          | 27.1 ± 38.1  | 501   | 27.9 ± 30.6    | <.001 |
| Lactate dehydrogenase (U/L)         | 4520              | 128.0 ± 27.8 | 500   | 129.4 ± 27.1   |       |

Abbreviations: LTBI, latent tuberculosis infection; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; HOMA-IR, homeostatic model assessment insulin resistance; HbA1c (%), glycosylated hemoglobin; RBC, red blood cells.

*Percentages are for unweighted frequency.

**Significant difference between control and LTBI cases was carried out by \( \chi^2 \) test or Student’s \( t \)-test. Only significant differences are shown.

*Diabetes is defined as Hb1Ac \( \geq 6.5\% \) or self-reported cases as per survey questionnaire.

---

However, there was a statistically significant difference between the means of the different BMI subgroups in both LTBI and control groups for the examined cardiometabolic risk markers \((P_{\text{trend}}: .021 \text{ to } <.001)\). Levels of vitamin B12 were significantly lower in the LTBI underweight subgroup compared to their control counterparts \((P=.037)\). Despite the significant difference between RBC folate and serum folic acid between the entire LTBI and control groups, there was no significant difference in their levels between LTBI and control groups in each of the BMI subcategories. However, there was a trend toward increased RBC folate and decreased serum folic acid in both study groups as the BMI increases \((P_{\text{trend}} <.001)\). Except for the alkaline phosphatase levels in the obese subgroups that was higher in the LTBI than controls \((P=.038)\), liver enzymes did not show significant differences at the different BMI subgroups between LTBI and controls.
Table 2. Sociodemographic characteristics and levels of potential cardiometabolic risk factors stratified by presence or absence of latent tuberculosis infection and by body mass index, U.S. National Health and Nutrition Examination Survey (NHANES), 2011/2012.

| CHARACTERISTIC | UNDERWEIGHT (BMI: < 18.5 KG/M²) | NORMAL WEIGHT (BMI: 18.5-24.9 KG/M²) | OVERWEIGHT (BMI: 25-29.9 KG/M²) | OBESE (BMI: >30 KG/M²) | CONTROL (N = 1010) | LTBI (N = 121) | CONTROL (N = 1412) | LTBI (N = 162) | CONTROL (N = 1486) | LTBI (N = 177) | CONTROL (N = 1631) | LTBI (N = 163) | CONTROL (N = 1625) | LTBI (N = 179) | CONTROL (N = 1625) | LTBI (N = 179) |
|----------------|----------------------------------|-------------------------------------|---------------------------------|------------------------|---------------------|----------------|-----------------|----------------|------------------|----------------|------------------|----------------|-------------------|----------------|-------------------|----------------|
| Males (%)a    | 33.7                             | 58.3                                | 48.4                            | 61.1                   | 54.6                | 62.1           | 56.4            | 62.1           | 54.6              | 62.1           | 54.6              | 62.1           | 54.6              | 62.1           | 54.6              | 62.1           |
| Age (years)   | 36.8 ± 20.4                      | 59.8 ± 22.6                         | 53.4 ± 16.8                     | .002                   | 48.1 ± 18.1         | 57.1 ± 14.5     | .001            | 47.6 ± 17.2     | 56.3 ± 14.9       | .001            | 47.6 ± 17.2       | 56.3 ± 14.9     | .001              | 47.6 ± 17.2       | 56.3 ± 14.9       | .001              |
| Age group in years (%) | 18-30                            | 31-50                               | 51-70                           | >70                    | 18-30               | 31-50           | 51-70           | >70             | 18-30             | 31-50           | 51-70             | >70             | 18-30             | 31-50           | 51-70             | >70             |
| Ethnicity (%) | White                             | Black                               | Asian                           | Hispanic and other     | Less than grade 12  | 16.7            | 16.7            | 16.7           | 16.7             | 16.7            | 16.7            | 16.7            | 16.7             | 16.7            | 16.7             | 16.7            |
| Highest level of education (%) | High-school graduate              | Post-secondary graduate             | Ratio of family income to poverty | History of intravenous drug use (%) | Smoking status (%) | Daily/occasional | Non-smoker | Diabetes (%)c | Cardiometabolic risk markers | Systolic blood pressure (mmHg) | 115 ± 24 | 150 ± 41 | .021 | 120 ± 19 | 125 ± 21 | .006 | 123 ± 18 | 124 ± 17 | .001 | 126 ± 17 | 128 ± 16 | .001 | 126 ± 17 | 128 ± 16 | .001 | 126 ± 17 | 128 ± 16 | .001 |
|                |                                  |                                     |                                 |                        |                     |                 |                 |                 |                                 | Diastolic blood pressure (mmHg) | 67 ± 10 | 71 ± 21 |        | 69 ± 12 | 70 ± 12 | .016 | 71 ± 12 | 70 ± 13 | .001 | 73 ± 13 | 72 ± 14 | .001 | 73 ± 13 | 72 ± 14 | .001 | 73 ± 13 | 72 ± 14 | .001 |
|                |                                  |                                     |                                 |                        |                     |                 |                 |                 |                                 | Triglycerides, fasting (mmol/L) | 1.00 ± 0.6 | 1.26 ± 1.0 | .016 | 1.28 ± 0.9 | 1.56 ± 1.4 | .001 | 1.73 ± 1.4 | 2.0 ± 1.4 | .001 | 1.95 ± 1.7 | 1.87 ± 1.3 | .001 | 1.95 ± 1.7 | 1.87 ± 1.3 | .001 | 1.95 ± 1.7 | 1.87 ± 1.3 | .001 |
|                |                                  |                                     |                                 |                        |                     |                 |                 |                 |                                 | Total cholesterol (mmol/L) | 4.48 ± 0.9 | 4.63 ± 1.0 |        | 4.82 ± 1.1 | 4.96 ± 1.1 | .001 | 5.01 ± 1.1 | 5.2 ± 1.1 | .001 | 5.0 ± 1.1 | 5.0 ± 1.0 | .001 | 5.0 ± 1.1 | 5.0 ± 1.0 | .001 | 5.0 ± 1.1 | 5.0 ± 1.0 | .001 |
|                |                                  |                                     |                                 |                        |                     |                 |                 |                 |                                 | LDL-C (mmol/L) | 2.47 ± 0.6 | 2.10 ± 0.5 |        | 2.79 ± 0.9 | 2.91 ± 0.8 | .001 | 3.0 ± 0.9 | 2.9 ± 0.8 | .001 | 3.0 ± 0.92 | 3.0 ± 1.0 | .001 | 3.0 ± 0.92 | 3.0 ± 1.0 | .001 | 3.0 ± 0.92 | 3.0 ± 1.0 | .001 |

(Continued)
| CHARACTERISTIC | UNDERWEIGHT (BMI: < 18.5 kg/m²) | NORMAL WEIGHT (BMI: 18.5-24.9 kg/m²) | OVERWEIGHT (BMI: 25-29.9 kg/m²) | OBESITY (BMI: ≥ 30 kg/m²) | CONTROL | LTBI | P<sub>adj</sub> | TB | P<sub>adj</sub> |
|---------------|----------------------------------|--------------------------------------|----------------------------------|--------------------------|---------|------|---------|---------|
| HDL-C (mmol/L) | 1.59 ± 0.41                      | 1.48 ± 0.41                         | 1.50 ± 0.39                     | 1.43 ± 0.40              | 1.36 ± 0.4 | 1.29 ± 0.3 | .049  | 1.23 ± 0.31 | 1.23 ± 0.33 | <.001  | <.001  |
| Total cholesterol:LDL-C ratio | 2.91 ± 0.71                      | 3.32 ± 1.15                         | 3.38 ± 1.0                      | 3.71 ± 1.29              | 3.93 ± 1.3 | 4.2 ± 1.2   | .003  | 4.3 ± 1.37  | 4.28 ± 1.25 | <.001  | <.001  |
| Insulin, fasting (pmol/L) | 45.3 ± 37.7                      | 38.2 ± 15.1                         | 47.1 ± 30.6                     | 55.2 ± 43.4              | 75.9 ± 78.1 | 78.9 ± 51.5 | <.001 | 118 ± 75     | 120 ± 90.6  | <.001  | .023   |
| Glucose, fasting (mmol/L) | 5.26 ± 0.72                      | 5.68 ± 0.49                         | 5.52 ± 1.52                     | 5.72 ± 1.19              | 5.81 ± 1.6 | 6.26 ± 1.6  | .018  | 6.44 ± 2.24  | 6.98 ± 2.8  | <.001  | .001   |
| HOMA-IR | 10.6 ± 8.85                      | 9.75 ± 4.16                         | 11.9 ± 10.6                     | 14.9 ± 15.8              | 20.3 ± 30.9 | 23.3 ± 22.3 | <.001 | 35.1 ± 28.5  | 38.2 ± 36.1 | <.001  | .015   |
| HbA1c (%) | 5.26 ± 0.40                      | 5.94 ± 0.45                         | 5.50 ± 0.91                     | 5.87 ± 1.29              | 5.68 ± 1.0 | 5.93 ± 1.1  | <.001 | 6.01 ± 1.29  | 6.33 ± 1.32 | <.001  | .001   |
| Apolipoprotein B, fasting (g/L) | 0.74 ± 0.19                      | 0.62 ± 0.14                         | 0.81 ± 0.23                     | 0.89 ± 0.22              | 0.91 ± 0.25 | 0.91 ± 0.21 | <.001 | 0.94 ± 0.24  | 0.94 ± 0.25 | <.001  | .021   |
| Vitamins and minerals |                      |                                      |                                  |                          |         |      |         |         |
| Vitamin B12 (µmol/L) | 494 ± 226                        | 389 ± 130                           | 482 ± 376                       | 486 ± 311               | 457 ± 329 | 443 ± 248 | <.001 | 453 ± 386    | 488 ± 379   | <.001  | <.001  |
| RBC folate (nmol/L) | 959 ± 60.9                       | 874 ± 392                           | 1042 ± 440                      | 1006 ± 391              | 1116 ± 514 | 1032 ± 412 | <.001 | 1140 ± 547   | 1197 ± 520  | <.001  | <.001  |
| Folic acid, serum (µmol/L) | 3.35 ± 9.93                      | 5.41 ± 15.3                         | 3.12 ± 14.8                     | 2.02 ± 4.81              | 2.48 ± 9.0 | 2.37 ± 7.09 | <.001 | 1.96 ± 6.3    | 1.46 ± 2.28 | <.001  | <.001  |
| Serum folate (nmol/L) | 45.8 ± 29.2                      | 41.7 ± 28.1                         | 47.7 ± 30.4                     | 45.9 ± 21.9              | 46.5 ± 28.8 | 47.9 ± 25.5 | <.001 | 43.1 ± 25.4   | 45.4 ± 22.4 | <.001  | <.001  |
| Sodium (mmol/L) | 139 ± 2.4                        | 139 ± 1.82                          | 139 ± 2.21                      | 139 ± 3.8               | 139 ± 2.22 | 139 ± 1.82 | <.001 | 139 ± 2.23   | 139 ± 12.2  | <.001  | <.001  |
| Potassium (mmol/L) | 3.85 ± 0.41                      | 3.70 ± 0.35                         | 3.91 ± 0.34                     | 3.93 ± 0.38             | 3.95 ± 0.33 | 3.97 ± 0.33 | <.001 | 3.95 ± 0.35   | 3.96 ± 0.36 | <.001  | <.001  |
| Calcium (mmol/L) | 2.37 ± 0.10                      | 2.32 ± 0.08                         | 2.36 ± 0.08                     | 2.34 ± 0.11            | 2.35 ± 0.10 | 2.35 ± 0.08 | <.001 | 2.34 ± 0.09   | 2.32 ± 0.10 | <.001  | .035   |
| Liver enzyme markers |                      |                                      |                                  |                          |         |      |         |         |
| Alanine aminotransferase (U/L) | 177 ± 11.3                       | 19.2 ± 8.9                          | 21.1 ± 17.9                     | 24.1 ± 24.6             | 24.3 ± 15.6 | 24.2 ± 12.9 | <.001 | 26.2 ± 38.5   | 277 ± 24.5   | <.001  | <.001  |
| Alkaline phosphatase (U/L) | 60.6 ± 22.1                      | 67.3 ± 21.1                         | 63.3 ± 21.6                     | 64.5 ± 18.9             | 66.9 ± 21.4 | 68.6 ± 25.3 | .036  | 72.1 ± 28.1   | 76.2 ± 23.3  | <.001  | <.001  |
| Aspartate aminotransferase (U/L) | 24.9 ± 23.3                      | 40.2 ± 59.8                         | 24.8 ± 15.1                     | 26.9 ± 19.9            | 25.3 ± 11.9 | 25.2 ± 10.5 | .046  | 26.3 ± 20.9   | 26.4 ± 14.0  | <.001  | <.001  |
| γ-Glutamyl transferase (U/L) | 21.5 ± 55.5                      | 20.1 ± 17.7                         | 22.5 ± 43.7                     | 24.8 ± 30.8            | 27.8 ± 34.3 | 25.9 ± 23.7 | <.001 | 30.8 ± 34.2   | 33.7 ± 36.5  | <.001  | .026   |
| Lactate dehydrogenase (U/L) | 120 ± 29                         | 140 ± 51                            | 124 ± 28                        | 127 ± 27               | 126 ± 25.6 | 128 ± 26.7  | <.001 | 132 ± 29      | 132 ± 25    | <.001  | <.001  |

Abbreviations: LTBI, latent tuberculosis infection; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; HOMA-IR, homeostatic model assessment insulin resistance; HbA1c (%), glycosylated hemoglobin; RBC, red blood cells.

*Percentages shown are for unweighted frequency.

**Significant difference between control and LTBI cases was carried out by γ² test or Student’s t-test. Only significant differences are shown.

*Diabetes is defined as HbA1c > 6.5% or self-reported cases as per survey questionnaire.
Infectious Diseases: Research and Treatment

Relationship between BMI and LTBI

In a partial correlation analysis between BMI and LTBI, BMI was inversely correlated with the prevalence of LTBI ($r = -0.134, P < .01$); this inverse correlation increased when data were adjusted for age and sex ($r = -0.147, P < .001$). Association between BMI and levels of cardiometabolic risk markers in the study population stratified by LTBI is shown in Table 3. When adjusted for age, sex, and ethnicity, both control and LTBI groups exhibited a similar profile of correlation between BMI and cardiometabolic risk markers. In general, increasing BMI was significantly associated with elevated levels of cardiometabolic risk markers such as fasting insulin, HOMA-IR, total cholesterol:HDL-C ratio, fasting glucose, fasting triglycerides, HbA1c, and LDL-C and with lower levels of HDL-C.

Multivariate logistic regression models used to estimate OR adjusted for potential confounders (95%CI) for LTBI with increasing BMI is shown in Table 4. Age, sex, diabetes, and level of education were the main confounders in the association between increasing BMI and lower prevalence of LTBI. When adjusted for age, sex, and diabetes, OR for LTBI was 0.88 (95%CI: 0.79-0.98; $P = .026$). When this model was further adjusted for the level of education, the OR decreased to 0.85 (95%CI: 0.77-0.96, $P = .01$). The addition of smoking, injection drug use, and ethnicity to the model did not affect the odds of LTBI associated with increasing BMI.

Discussion

Our analyses of NHANES data from 2011/2012 reveal an inverse relationship between BMI and prevalence of LTBI when adjusted for age and sex. These results are consistent with previous reports substantiating such an inverse relationship that appears to be continuous across BMI categories, from underweight through to obesity. As an example of the inverse relationship seen between BMI and TB incidence, a cohort of >65-years-old individuals who were followed for 5 years in Hong Kong, a hazard ratio was noted of 0.9 (95%CI: 0.87-0.93) for TB per unit increase in BMI. This TB risk reduction with increasing BMI has been, however, specific for pulmonary TB but not for the extrapulmonary disease. When the effect of BMI was evaluated on all-cause and causes-specific mortality, a similar inverse association between obesity and TB has been observed both globally and regionally, eg, in India.

Although the exact mechanism for the inverse relationship between obesity and TB is yet to be fully understood, it was postulated that nutritional factors and the related adiposity may influence the capacity of the immune system to combat TB and other infections. The role of cytokine-mediated innate immunity in host protection against $M. tuberculosis$ infection has been demonstrated in numerous experimental models of infection and established a critical role for interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukins (ILs) in

Table 3. Correlation between body mass index and levels of potential cardiometabolic risk factors stratified by presence or absence of latent tuberculosis infection, U.S. National Health and Nutrition Examination Survey (NHANES), 2011/2012.

| RISK MARKER                        | CONTROLS | LTBI          | CONTROLS | LTBI          |
|-----------------------------------|----------|---------------|----------|---------------|
| R                                 | $p$      | R             | $p$      | R             |
| Systolic blood pressure (mmHg)    | 0.138    | $< .001$      | −0.014   |               |
| Diastolic blood pressure (mmHg)   | 0.145    | $< .001$      | 0.021    |               |
| Triglycerides, fasting (mmol/L)   | 0.213    | $< .001$      | 0.211    | .002          |
| Total cholesterol (mmol/L)        | 0.003    |               | −0.062   |               |
| LDL-C (mmol/L)                    | 0.065    | .006          | −0.027   |               |
| HDL-C (mmol/L)                    | −0.338   | $< .001$      | −0.315   | $< .001$      |
| Total cholesterol:HDL-C ratio     | 0.299    | $< .001$      | 0.257    | $< .001$      |
| Insulin, fasting (pmol/L)         | 0.470    | $< .001$      | 0.368    | $< .001$      |
| Glucose, fasting (mmol/L)         | 0.224    | $< .001$      | 0.218    | .002          |
| HOMA-IR                           | 0.399    | $< .001$      | 0.372    | $< .001$      |
| HbA1c (%)                         | 0.212    | $< .001$      | 0.254    | $< .001$      |
| Apolipoprotein B, fasting (g/L)   | 0.165    | $< .001$      | 0.067    |               |

Abbreviations: LTBI, latent tuberculosis infection; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; HOMA-IR, homeostatic model assessment insulin resistance; HbA1c (%), glycated hemoglobin.

*Correlation coefficients between BMI and the cardiometabolic risk markers were adjusted for age, sex, and ethnicity.

*Only significant values are shown.
Adipocyte and the immune cells within the adipose tissue secrete elevated levels of these inflammatory mediators to influence insulin sensitivity, inflammation, and innate and adaptive immune responses.

When the relationship between LTBI and obesity was adjusted for age, sex, and diabetes, we noted a significant lowering in the odds of LTBI (OR = 0.87, 95% CI: 0.79-0.97; \( P = .019 \)). It was proposed that prolonged persistence of *M. tuberculosis* (ie, LTBI) may result in alerted levels of cardiometabolic risk markers. Such an altered metabolic profile is known to result in increased synthesis of cytokines and acute phase reactants such as C-reactive protein (CRP) in normal individuals and in TB patients leading to a lower proliferation rates of T-cell subsets and modification of their functions. There is a possibility for a particular metabolic profile to arise in LTBI patients to prevent the emergence of TB and may result in weight lowering. This, together with the observation that the economic status of the control group was higher than the LTBI group, both should be considered in developing LTBI apart from the findings of the serologic or metabolic profiles observed in this study population.

An increased risk of LTBI has been observed in underweight subjects. This may be explained by the theory that malnutrition predisposes to increased vulnerability to LTBI and TB through mechanisms related to compromised immune and thymic function. Low plasma leptin, eg, in the malnourished state, was linked to impairment of the immune response. This is in contrast to the high leptin concentrations known to occur in obesity as a result of the increased fat mass. Leptin promotes proliferation and activation of T lymphocytes upon mitogen stimulation. The general consensus is, therefore, that leptin may serve as a protective factor against infections, a proposition that may explain observations showing that low body weight is associated with risk of TB, disease severity, and unfavorable response to treatment. Furthermore, higher mortality among underweight TB patients was also proposed to be due to decreased immunity and a greater severity of TB infection. Being underweight reduces the number of lymphocyte, leading to a higher risk of TB infection and/or increased disease severity in underweight patients. Taken together, animal models infected with *M. tuberculosis* showed that malnourishment result in impairment of the immune system, higher bacterial burden, and early death following infection.

The present report has several limitations. We only considered BMI as an indicator of obesity. Waist circumference and waist-to-hip ratio could have been also included. However, these factors would have prevented categorizing the degree of obesity to the extent generated when using BMI as an indicator. Another limitation is that we did not consider the interaction between LTBI, obesity, and metabolic syndrome-related morbidities other than diabetes (eg, cardiovascular or kidney diseases) given the well-established interaction and convergence between the increasing BMI and these chronic conditions. Self-report of diabetes is problematic since up to 30% of diabetes in the US is undiagnosed. This level is presumed even higher among immigrants and the economically marginalized. The actual versus reported prevalence of diabetes may have affected the impact of confounders in the present study. Most importantly, the inverse relationship between obesity and LTBI observed here reflects an association between the 2 conditions but should not be construed as an inference of causality. We did not explore other factors contributing to increases or decreases in BMI that may also have independent effects on LTBI prevalence such as the role and effect of malnutrition, adiposity, synthesis of pro-inflammatory cytokines, plasma leptin, and tuberculosis reporting rate in country of origin.

### Table 4. Odds for having presence or absence of latent tuberculosis infection with increased body mass index using multivariate logistic regression, U.S. National Health and Nutrition Examination Survey (NHANES), 2011/2012.

| MODEL ADJUSTMENT | OR  | 95% CI       | \( P \) |
|------------------|-----|--------------|--------|
| No LTBI          | 1   | Ref          | —      |
| Crude            | 0.94| 0.84-1.04    | .538   |
| Age              | 0.89| 0.80-0.98    | .038   |
| Diabetes         | 0.90| 0.82-0.97    | .049   |
| Age and sex      | 0.89| 0.80-0.99    | .048   |
| Age and diabetes | 0.87| 0.79-0.97    | .019   |
| Age, sex, and diabetes | 0.88| 0.79-0.98    | .026   |
| Age, sex, diabetes, and education | 0.85| 0.77-0.96    | .010   |

Abbreviations: LTBI, latent tuberculosis infection. ORs are in a descending order within the adjusted models.

Multivariate logistic regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) between BMI and LTBI.

Only significant values are shown.
In conclusion, the present study evaluated the relation of LTBI risk with BMI and demonstrated an inverse association between BMI and risk of having LTBI in a model adjusted for age and sex. This underscores an epidemiologic inverse association of body weight with the development of LTBI, and by extension, a potential inverse association of body weight with the subsequent development of TB. The inverse relationships between prevalence of obesity and incidence of LTBI and between having diabetes mellitus (in which obesity is a risk factor) and developing TB itself underscore a need to examine further the relationship between obesity and all forms of TB infection.

Author Contribution
AB conceived the study idea and design, data analysis, analysis and interpretation, and wrote the manuscript. CJL assisted in data analysis. All authors critically reviewed the manuscript, approved the final draft and agreed to be accountable for all aspects of the work.

ORCID iD
Christina J Liu https://orcid.org/0000-0001-9375-1361

REFERENCES
1. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018;18:1329-1349.
2. World Health Organization (WHO). Global Tuberculosis Report, 2019. WHO, 2019. https://www.who.int/tbr/publications/global_report/en/
3. Kahwati LC, Feltner C, Halpern M, et al. Screening for latent tuberculosis infection in adults: an evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (US). Evid Synth. 2016;142. https://www.ncbi.nlm.nih.gov/books/NBK385124
4. Getahun H, Mattelii A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127-2135.
5. Uplekar M, Wiel D, Lönnroth K, et al. WHO’s new end TB strategy. Lancet. 2015;385:1799-1801.
6. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Ann Rev Public Health. 2013;34:271-286.
7. Zhang X, Jia H, Liu F, et al. Prevalence and risk factors for latent tuberculosis infection in subjects with diabetes mellitus (DM). PLoS ONE. 2013;8:e66442. doi:10.1371/journal.pone.0066442
8. Sarivalias A, Zellweger JP, Faouzi M, Daher O, Deslarzes C, Bodenmann P. Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County. BMC Infect Dis. 2012;12:285. doi:10.1186/1471-2334-12-285
9. Lule SA, Mawa PA, Nkurungu G, et al. Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five-year-old BCG-immunised at birth in Entebbe, Uganda. Faccine. 2015;33:796-804.
10. Martinez-Aguilar G, Serrano CJ, Castañeda-Delgado JE, et al. Associated risk factors for latent tuberculosis infection in subjects with diabetes. Arch Med Res. 2015;46:221-227.
11. Rizza FN, List J, Nkawata AK, et al. Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. BMC Infect Dis. 2015;15:165. doi:10.1186/1471-2851-15-165
12. Odone A, Houben RM, White RG, Lönnroth K. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol. 2014;2:754-764.
13. Tverdal A. Body mass index and incidence of tuberculosis. Eur J Respir Dis. 1986;69:355-362.
14. Cegielski JP, McMurry DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis. 2014;8:286-298.
15. Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39:149-155.
16. Roth J, Sahota N, Patel P, et al. Obesity paradox, obesity orthodoxos, and the metabolic syndrome: an approach to unity. Med Med. 2016;22:873-885.
17. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: epidemiology and clinical management. Chest. 2017;152:165-173.
18. Nattrass FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today. 2015;50:117-128.
19. Cubilla-Batista I, Ruiz N, Sambrano D, et al. Overweight, obesity, and older age favor latent tuberculosis infection among household contacts in low tuberculosis-incidence settings within Panama. Am J Trop Med Hyg. 2019;100:1141-1144.
20. Zhang H, Li X, Xin H, et al. Association of body mass index with the tuberculosis infection: a population-based study among 17796 adults in rural China. Sci Rep. 2017;7:41933. doi:10.1038/srep41933
21. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014;2:740-753.
22. Rizza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2:740-753.
23. Badawi A, Sayegh S, Sallam M, et al. The global relationship between the prevalence of diabetes mellitus and incidence of tuberculosis: 2000–2012. Glob Tuberc Sci. 2014;7:181-191.
24. Greerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEBS Journals. 1999;26:259-265.
25. Mohajer LMJ, Montijo J, Wakeberg, et al. National Health and Nutrition Examination Survey III: weighting and examination methodology. 1996. https://ceb.nlm.nih.gov/proj/dxspnet/shanes/docs/shanes_analysis/wgt_exec.pdf
26. Barron MM, Shaw KM, Bullard KM, Ali MK, Magee MJ. Diabetes is associated with increased prevalence of latent tuberculosis infection: findings from the National Health and Nutrition Examination Survey, 2011-2012. Diabetes Res Clin Pract. 2018;139:366-379.
27. Curtin LR, Mohajer LK, Dohrmann SM, et al. National health and nutrition examination survey: sample design, 2007–2010. Vital Health Stat 2. 2013;160:1-23.
28. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National health and nutrition examination survey: sample design, 2011-2014. Vital Health Stat 2. 2014;162:1-33.
29. Maceure GH, Jered J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States. MMWR Recomm Rep. 2010;59:273-279.
30. Miramontes R, Hill AN, Yolk Woodruff RS, et al. Tuberculosis Infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One. 2015;10:e0140881. doi:10.1371/journal.pone.0140881
31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care. 2010;33:562-569.
32. Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752.
33. Brenner DR, Arora P, Garcia-Bailo B, et al. Plasma vitamin D levels and risk of metabolic syndrome in Canadians. Clin Invest Med. 2011;34:E377. doi:10.25011/cim.v34i4.15899
34. Setayeshgar S, Whiting SJ, Vatanparast H. Prevalence of 10-year risk of cardiovascular diseases and associated risks in Canadian adults: the contribution of car- diovascular metabolic risk assessment introduction. Int J Hydr. 2013;2013:276564. doi:10.1155/2013/276564
35. Matthews DR, Hopper JK, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
36. Badawi A, Sayegh S, Sadou E, Al-Thani M, Arora P, Haddad PS. Relationship between insulin resistance and plasma vitamin D in adults. Diabetes Metab Syndr Obes. 2014;7:297-303.
37. CDC. National Health and Nutrition Examination Survey. 2011–2012 Data Documentation, Codebook, and Frequencies. National Center for Health Statistics; 2013.
38. Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: results from two general population health surveys in Canada and the United States (2007-2017). PLoS ONE. 2018;13:e0208839. doi:10.1371/journal.pone.0208839
39. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med. 2007;167:1297-1304.
40. Prospective Studies Collaboration, Whitlock G, Lewinigon S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.

Infectious Diseases: Research and Treatment
41. Pednekar MS, Hakama M, Hebert JR, Gupta PC. Association of body mass index with all-cause and cause-specific mortality: findings from a prospective cohort study in Mumbai (Bombay), India. *Int J Epidemiol*. 2008;37:524-535.

42. James WP, Ferro-Luzzi A, Waterlow JC. Definition of chronic energy deficiency in adults. Report of a working party of the International Dietary Energy Consultative Group. *Eur J Clin Nutr*. 1988;42:969-981.

43. Karlsson EA, Beck MA. The burden of obesity on infectious disease. *Exp Biol Med*. 2010;235:1412-1424.

44. Moreira-Teixeira L, Mayer-Barber K, Sher A, O'Garra A. Type I interferons in tuberculosis: foe and occasionally friend. *J Exp Med*. 2018;215:1273-1285.

45. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. *Diabetes Res Clin Pract*. 2005;69:29-35.

46. Philips L, Visser J, Nel D, Blauw R. The association between tuberculosis and the development of insulin resistance in adults with pulmonary tuberculosis in the Western sub-district of the Cape Metropole region, South Africa: a combined cross-sectional, cohort study. *BMC Infect Dis*. 2017;17:570. doi:10.1186/s12879-017-2657-5

47. Da Costa LA, Arora P, Garcia-Bailo B, Karmali M, El-Sohemy A, Badawi A. The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults. *Diabetes Metab Syndr Obes*. 2012;5:347-355.

48. Lawn SD, Obeng J, Achachempong JW, Griffin GE. Resolution of the acute-phase response in West African patients receiving treatment for pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2000;4:340-344.

49. Nieman DC, Nehlsen-Cannarella SL, Henson DA, et al. Immune response to obesity and moderate weight loss. *Int J Obes Relat Metab Disord*. 1996;20:353-360.

50. Nieman DC, Henson DA, Nehlsen-Cannarella SL, et al. Influence of obesity on immune function. *J Am Diet Assoc*. 1999;99:294-299.

51. Bhargava A, Pai M, Bhargava M, et al. Can social interventions prevent tuberculosis?: The Papworth experiment (1918-1943) revisited. *Am J Respir Crit Care Med*. 2012;186:442-449.

52. Macallan DC. Malnutrition in tuberculosis. *Diagn Microbial Infect Dis*. 1999;34:153-157.

53. Villanmor E, Iliadou A, Chattingius S. Evidence for an effect of fetal growth on the risk of tuberculosis. *J Infect Dis*. 2010;201:409-413.

54. Palacio A, Lopez M, Perez-Braio F, Monkeberg F, Schlesinger L. Leptin levels are associated with immune response in malnourished infants. *J Clin Endocrinol Metab*. 2002;87:3040-3046.

55. Procaccini C, Lourenco EV, Matarase G, La Cava A. Leptin signaling: a key pathway in immune responses. *Curr Signal Transduct Ther*. 2009;4:22-30.

56. La Cava A, Alviggi C, Matarase G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. *J Mol Med*. 2004;82:4-11.

57. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol*. 2005;115:911-920.

58. Zachariah R, Spielmann MP, Harries AD, Salaniponi FML. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. *Trans R Soc Trop Med Hyg*. 2002;96:291-294.

59. Chan J, Tian Y, Tanaka KE, et al. Effects of protein calorie malnutrition on tuberculosis in mice. *Proc Natl Acad Sci USA*. 1996;93:14857-14861.

60. Badawi A, Drebot M, Ogden NH. Convergence of chronic and infectious diseases: a new direction in public health policy. *Can J Public Health*. 2019;110:523-524.